Literature DB >> 12584637

Endoscopic mucosal resection in the management of gastric carcinoid tumors.

J Ichikawa1, S Tanabe, W Koizumi, Y Kida, H Imaizumi, M Kida, K Saigenji, H Mitomi.   

Abstract

BACKGROUND AND STUDY AIMS: Gastric carcinoid tumors are a rare disease. Previously, total gastrectomy was regarded as the treatment of choice. However, differences in biological malignancy have recently led to the increased use of endoscopic mucosal resection (EMR) for treatment. We studied the outcome of EMR in patients with gastric carcinoids who were treated at our hospital and discuss the indications for endoscopic treatment. PATIENTS AND METHODS: Between 1986 and 1999 we carried out gastric mucosal resection in five patients with gastric carcinoid tumors. The procedure used for EMR was either strip biopsy or endoscopic aspiration mucosectomy.
RESULTS: The carcinoid tumors measured 10 mm or less in four of the five patients. Two patients had type A gastritis, and all had hypergastrinemia. There was no evidence of recurrence during follow-up (range 6 - 66 months; mean 32.6 months).
CONCLUSION: EMR is useful in the management of type 1 gastric carcinoids as classified by Rindi (hypergastrinemia; tumor diameter of 10 mm or less).

Entities:  

Mesh:

Year:  2003        PMID: 12584637     DOI: 10.1055/s-2003-37256

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  33 in total

Review 1.  Surgical treatment of gastrointestinal neuroendocrine tumors.

Authors:  Volker Fendrich; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2011-02-01       Impact factor: 3.445

2.  Long-term follow up of endoscopic resection for type 3 gastric NET.

Authors:  Yong Hwan Kwon; Seong Woo Jeon; Gwang Ha Kim; Jin Il Kim; Il-Kwun Chung; Sam Ryong Jee; Heung Up Kim; Geom Seog Seo; Gwang Ho Baik; Kee Don Choi; Jeong Seop Moon
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

3.  Unexpected endoscopic full-thickness resection of a duodenal neuroendocrine tumor.

Authors:  Ken Hatogai; Yasuhiro Oono; Kuang-I Fu; Tomoyuki Odagaki; Hiroaki Ikematsu; Takashi Kojima; Tomonori Yano; Kazuhiro Kaneko
Journal:  World J Gastroenterol       Date:  2013-07-14       Impact factor: 5.742

Review 4.  Endoscopic diagnosis and management of type I neuroendocrine tumors.

Authors:  Yuichi Sato
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

Review 5.  Clinical features and management of type I gastric carcinoids.

Authors:  Yuichi Sato
Journal:  Clin J Gastroenterol       Date:  2014-09-17

6.  Clinicopathological characteristics and frequency of multiple rectal neuroendocrine tumors: a single-center retrospective study.

Authors:  Yusuke Nishikawa; Akiko Chino; Daisuke Ide; Shoichi Saito; Masahiro Igarashi; Manabu Takamatsu; Junko Fujisaki; Yoshinori Igarashi
Journal:  Int J Colorectal Dis       Date:  2019-10-19       Impact factor: 2.571

Review 7.  How should incidental NEN of the pancreas and gastrointestinal tract be followed?

Authors:  Riccardo Ariotti; Stefano Partelli; Francesca Muffatti; Valentina Andreasi; Francesca Della Sala; Massimo Falconi
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 8.  Perspective on the practical indications of endoscopic submucosal dissection of gastrointestinal neoplasms.

Authors:  Mitsuhiro Fujishiro
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

9.  Gastric carcinoid tumor in a patient with a past history of gastrointestinal stromal tumor of the stomach.

Authors:  Chien-Yuan Hung; Ming-Jen Chen; Shou-Chuan Shih; Tsang-Pai Liu; Yu-Jan Chan; Tsang-En Wang; Wen-Hsiung Chang
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

10.  Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study.

Authors:  Quan-Lin Li; Yi-Qun Zhang; Wei-Feng Chen; Mei-Dong Xu; Yun-Shi Zhong; Li-Li Ma; Wen-Zheng Qin; Jian-Wei Hu; Ming-Yan Cai; Li-Qing Yao; Ping-Hong Zhou
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.